<h1>New Dual-Action Drug Approved for Treating Non-Alcoholic Fatty Liver Disease (NAFLD) Under Section 5</h1> A pharmaceutical company has obtained the first global regulatory approval for a novel therapy targeting Non-Alcoholic Fatty Liver Disease (NAFLD), granted by the national drug regulatory authority. The approved drug employs a dual-action mechanism addressing inflammation and bile acid regulation, aiming to prevent disease progression to more severe liver conditions. Clinical trials demonstrated the drug's efficacy and safety, with no significant adverse effects reported. The company plans immediate commercialization domestically and is pursuing international approvals to expand global access. This approval marks a significant development in treating a widespread liver disease affecting over a billion people worldwide.